Glucocorticoid Receptor
11 drugs Rare DiseaseRespiratoryMetabolic
5
approved indications
11
Approved Drugs
10
Companies
10
Indications
3
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (10 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (10 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
GSK 2 drugs
EVITA SOLUTIONS 1 drug
DANCO LABS LLC 1 drug
By Therapeutic Area
Respiratory 4 drugs
Metabolic 3 drugs
Drugs by Company PRO
GSK 2 drugs
EVITA SOLUTIONS 1 drug
DANCO LABS LLC 1 drug
CORCEPT THERAP 1 drug
BAUSCH AND LOMB INC 1 drug
UPSHER SMITH LABS 1 drug
PADAGIS ISRAEL 1 drug
AUCTA 1 drug
COVIS 1 drug
AMNEAL IRELAND LTD 1 drug
By Therapeutic Area
Respiratory 4 drugs
FLOVENT HFA, ADVAIR HFA, ALVESCO, BECLOMETHASONE DIPROPIONATE
Metabolic 3 drugs
MIFEPRISTONE, MIFEPREX, KORLYM
Other 2 drugs
XIPERE, AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
Rare Disease 2 drugs
DEFLAZACORT, PYQUVI
Indications Treated
Duchenne Muscular DystrophyAsthmaSeasonal Allergic RhinitisMacular EdemaUveitisHyperglycemiaHypercortisolismCushing's SyndromeType 2 DiabetesGlucose Intolerance
All Drugs Targeting Glucocorticoid Receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| MIFEPRISTONE | EVITA SOLUTIONS | 2019 | 5 | Metabolic |
| MIFEPREX | DANCO LABS LLC | 2000 | 5 | Metabolic |
| KORLYM | CORCEPT THERAP | 2012 | 5 | Metabolic |
| XIPERE | BAUSCH AND LOMB INC | 2021 | 2 | |
| DEFLAZACORT | UPSHER SMITH LABS | 2024 | 1 | Rare Disease |
| FLOVENT HFA | GSK | 2004 | 1 | Respiratory |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | PADAGIS ISRAEL | 2017 | 1 | |
| PYQUVI | AUCTA | 2025 | 1 | Rare Disease |
| ADVAIR HFA | GSK | 2006 | 1 | Respiratory |
| ALVESCO | COVIS | 2008 | 1 | Respiratory |
| BECLOMETHASONE DIPROPIONATE | AMNEAL IRELAND LTD | 2025 | 1 | Respiratory |